Brain-Directed Gene Therapy After Death in Neurogene Trial: What Comes Next

Last week, Neurogene reported a tragic event: a young girl with Rett syndrome who was treated with their gene therapy passed away. This news has led the company to pause the use of the high dose of the therapy that the girl received. However, they will continue testing a lower dose moving forward.

In early November, the girl received a high dose of the therapy as part of an ongoing clinical trial for girls between the ages of 4 and 10. After experiencing signs of a severe immune reaction, the U.S. Food and Drug Administration (FDA) reviewed safety data from a low-dose group and allowed the trial to proceed at that lower dose. Neurogene has decided not to enroll any more participants in the high-dose group based on this information.

Despite this setback, positive results have been seen in other participants of the trial. The first four girls in the low-dose group showed improvements in various areas and did not experience any serious adverse effects. One of the key aspects of this therapy is that it contains a gene that helps address the root cause of Rett syndrome, which is a lack of the MECP2 protein. This gene is delivered using a specific virus.

The unfortunate loss of a participant in the trial has shed light on the importance of understanding safe dosing levels for this type of gene therapy. While it is an incredibly sad event, it does not necessarily change the overall progress being made in therapy development. Researchers are continuously learning from these trials to improve therapies moving forward.

Neurogene’s plans have been adjusted following this event, with a focus on the safety of the participants. They are exploring different dosing strategies to ensure the well-being of all those involved in the trials. It’s essential to remember that these developments are part of the learning process when it comes to gene therapy research. Each data point, no matter how challenging, provides valuable insights for the future.